Ovarian Cancer

The Nectin-4/CD137 Bicycle–targeted immune cell agonist BT7480 had antitumor activity in patients with Nectin-4– and CD137-expressing tumors.

SHR-A1921 showcased early efficacy with a manageable safety profile in patients with platinum-resistant ovarian cancer.

A rolling NDA seeking the approval of avutometinib plus defactinib in recurrent KRAS-mutant low-grade serous ovarian cancer has been submitted to the FDA.

Laura J. Chambers, DO, discusses the roles of niraparib and olaparib in ovarian cancer and the importance of patient communication throughout treatment.

For more first-hand insights, head over to our YouTube channel to watch Dr Markman discuss the inner workings of oncology: https://rb.gy/bvumdn.

Zolbetuximab wins approval for CLDN18.2-positive gastric/GEJ cancer, TTFields joins the NSCLC armamentarium, and more of this week's top news in oncology.

Updated RAMP 201 data will support an NDA submission to the FDA for avutometinib plus defactinib in recurrent low-grade serous ovarian cancer.

Gotistobart plus pembrolizumab demonstrated antitumor activity and a manageable safety profile in platinum-resistant ovarian cancer.

The KIF18A inhibitor VLS-1488 has received fast track designation from the FDA for platinum-resistant high-grade serous ovarian cancer.

Angeles Secord, MD, MHSc, discusses data with mirvetuximab soravtansine in heavily pretreated FRα-positive recurrent, platinum-sensitive ovarian cancer.

The EMA’s CHMP has recommended the marketing authorization of mirvetuximab soravtansine for FRα-positive, platinum-resistant epithelial ovarian cancer.

Angeles A. Secord, MD, MHSc, discusses safety findings from the PICCOLO trial of mirvetuximab soravtansine in recurrent, platinum-sensitive ovarian cancer.

Datopotamab deruxtecan shows antitumor activity in patients with advanced/metastatic ovarian and endometrial cancer and progressive disease following platinum chemotherapy.

The FDA has lifted the partial clinical hold previously placed on studies evaluating azenosertib in advanced solid tumors.

TORL-1-23 was safe and active in heavily pretreated, Claudin-6–positive advanced solid tumors, including platinum-resistant ovarian cancer.

Angeles A. Secord, MD, MHSc, discusses the PICCOLO trial of mirvetuximab soravtansine in recurrent, platinum-sensitive, FRα-high ovarian cancer.

Treatment with maintenance olaparib/cediranib demonstrated similar survival vs olaparib alone in platinum-sensitive relapsed ovarian cancer.

Kimberly Cannavale, MPH, discusses the clinical implications of a study on the impact of pre-existing comorbidities on remission rates in ovarian cancer.

Kimberly Cannavale, MPH, discusses the rationale for investigating the effect of pre-existing comorbidities on remission rates in ovarian cancer.

Amma Asare, MD, PhD, discusses the elevated risk of therapy-related myeloid neoplasms or secondary leukemias in gynecologic cancers after a PARP inhibitor.

NXP800 was granted orphan drug designation by the FDA for the treatment of ARID1a-deficient ovarian, fallopian tube, and primary peritoneal cancers.

Kimberly Cannavale, MPH, discusses a study of the association between Charlson comorbidity index and complete remission in patients with ovarian cancer.

Jean-Marc Classe, MD, PhD, discusses omitting lymphadenectomy in patients with advanced epithelial ovarian cancer.

Ritu Salani, MD, discusses the role of ADCs in ovarian cancer and what the future of the post-IO setting in cervical cancer management may look like.

Laura J. Chambers, DO, discusses the role of genetic testing and PARP inhibitor maintenance therapy for patients with ovarian cancer.

Suvemcitug plus chemotherapy improved progression-free survival in platinum-resistant ovarian cancer.

Ceralasertib plus olaparib demonstrated clinical activity in platinum-sensitive, recurrent, high-grade serous ovarian cancer, regardless of HRD status.

IMNN-001 plus perioperative chemotherapy improved overall survival in newly diagnosed, advanced ovarian cancer.

Rezatapopt has displayed early signals of efficacy and tolerability in p53 Y220C-mutated solid tumors.

Don Dizon, MD, discusses updated findings from the BrUOG 354 trial and the future of immunotherapy for patients with ovarian cancers.